Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Piramal Life Sciences CEO Somesh Sharma On Managing Risk And India's Potential For Discovering New Drugs: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Piramal Life Sciences CEO Somesh Sharma keeps a very low profile and does not speak much about his three decades of leading start-ups in the U.S., but his passion for research has fueled the determination of the Piramal Healthcare group to discover and develop a new molecular compound - which would be a first for India's pharma industry.

You may also be interested in...



Piramal Life Sciences CEO Somesh Sharma On Managing Risk And India's Potential For Discovering New Drugs: An Interview With PharmAsia News (Part 1 of 2)

Piramal Life Sciences CEO Somesh Sharma keeps a very low profile and does not speak much about his three decades of leading start-ups in the U.S., but his passion for research has fueled the determination of the Piramal Healthcare group to discover and develop a new molecular compound - which would be a first for India's pharma industry.

Regenerative Meds: Indian Drug Makers Inject New Life Through Investments In Stem Cells

MUMBAI - Leading Indian companies are gearing up for emerging frontiers in medicine research, and among all the segments, regenerative therapies seem to be driving more and more initial investments from mainstream pharma companies

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years

Latest News
See All
UsernamePublicRestriction

Register

SC073329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel